Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2021 | Role of transplant in MRD negativity

Natalie Callander • 13 Dec 2021
ASH 2021
Multiple Myeloma
FORTE MASTER

In this video, Natalie Callander, MD, University of Wisconsin School of Medicine and Public Health, Madison, WI, briefly shares some insights on minimal residual disease (MRD)-directed therapy, highlighting the impact of autologous stem cell transplant (ASCT) on MRD negativity rates in the MASTER trial (NCT03224507) and the FORTE trial (NCT02203643). This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA, 2021.

More from Natalie Callander

0:46
The impact of daratumumab induction on stem cell collection in myeloma patients
Natalie Callander • 13 Dec 2021
2:22
DREAMM-5 sub-study: belamaf in combination with feladilimab in the treatment of R/R myeloma
Natalie Callander • 13 Dec 2021
2:04
Dara-KRd, transplant, and MRD response-adapted treatment in newly diagnosed myeloma
Natalie Callander • 6 Sep 2021
3:56
MRD highlights from the IMW meeting
Natalie Callander • 6 Sep 2021

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals